Phase 2 study of dasatinib in the treatment of head and neck squamous cell carcinoma

Abstract

Single-agent dasatinib failed to demonstrate significant activity in patients with advanced HNSCC, despite c-Src inhibition. The toxicity profile was consistent with that reported in other solid tumors, and the drug can be given via PFG tube.